4.8 Review

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks

Journal

JOURNAL OF HEPATOLOGY
Volume 66, Issue 2, Pages 424-441

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2016.09.010

Keywords

Cholangiocarcinoma; Epithelial-mesenchymal transition; Invasiveness; Chemoresistance; Tumor microenvironment

Funding

  1. Fondation de France [2014 00047502]
  2. La Ligue National contre le Cancer [RS14/75-112]
  3. Spanish Association for the Study of the Liver (AEEH)
  4. Fondation ARC [PDF2014601431]

Ask authors/readers for more resources

Cholangiocarcinoma (CCA) is an aggressive tumor with a poor prognosis due to its late clinical presentation and the lack of effective non-surgical therapies. Unfortunately, most of the patients are not eligible for curative surgery owing to the presence of metastases at the time of diagnosis. Therefore, it is important to understand the steps leading to cell dissemination in patients with CCA. To metastasize from the primary site, cancer cells must acquire migratory and invasive properties by a cell plasticity-promoting phenomenon known as epithelial-mesenchymal transition (EMT). EMT is a reversible dynamic process by which epithelial cells gradually adopt structural and functional characteristics of mesenchymal cells, and has lately become a centre of attention in the field of metastatic dissemination. In the present review, we aim to provide an extensive overview of the current clinical data and the prognostic value of different EMT markers that have been analysed in CCA. We summarize all the regulatory networks implicated in EMT from the membrane receptors to the main EMT-inducing transcription factors (SNAIL, TWIST and ZEB). Furthermore, since a tumor is a complex structure not exclusively formed by tumor cells, we also address the prominent role of the main cell types of the desmoplastic stroma that characterizes CCA in the regulation of EMT. Finally, we discuss the therapeutic considerations and difficulties faced to develop an effective anti-EMT treatment due to the redundancies and bypasses among the pathways regulating EMT. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available